查詢結果分析
來源資料
相關文獻
- 肝硬化併腹水病的利尿劑使用
- Midodrine治療肝硬化合併腹水之案例
- 肝硬化腹水利尿劑之選擇與使用
- 肝硬化腹水的治療
- 肝硬化腹水病例討論--養陰或利濕﹖
- Clinical Experience with the Peritoneovenous Shunt for Intractable Ascites
- 肝硬化腹水治療的新焦點
- 肝硬化併發症的治療--腹水和食道靜脈瘤
- 肝硬化腹水放液術
- Unusual Bilateral Peritoneopleural Communication Associated with Cirrhotic Ascites:Detected by TC-99M Sulphur Colloid Peritoneoscintigraphy
頁籤選單縮合
題名 | Midodrine治療肝硬化合併腹水之案例=Using Midodrine in a Patient with Cirrhosis and Ascites |
---|---|
作者 | 許永佳; 張瓊月; | 書刊名 | 藥學雜誌 |
卷期 | 30:4=121 2014.12[民103.12] |
頁次 | 頁91-96 |
分類號 | 415.534、415.534 |
關鍵詞 | 利尿劑; 肝硬化; 腹水; Midodrine; Refractory ascites; Diuretic-resistant ascites; |
語文 | 中文(Chinese) |
中文摘要 | 根據美國肝病研究學會 (AASLD) 之治療準則,肝硬化合併腹水病人的治療首先 需要戒除酒精與限制鈉攝取,而藥物治療通常優先採用利尿劑合併療法,若病人對利 尿劑產生抗性或難治性腹水時,則可建議加入第二線藥物或選擇外科手術方式進行治 療。本文報告的案例是一位肝硬化合併嚴重腹水病人,住院初期使用三種利尿劑合併 治療,經醫師評估病人排尿反應不佳後,調高利尿劑使用劑量,但每日尿液排除作用 仍不顯著。在加入第二線治療藥物 midodrine 後,病人尿液排出量明顯增加,下肢水 腫、腰圍與體重等臨床表徵皆有明顯改善。 |
英文摘要 | According to the guidelines of American Association for the Study of Liver Diseases (AASLD), patient with cirrhosis and ascites should abstain from alcohol, restrict sodium intake, and adopt combinational diuretics as first-line therapy. Second-line medications or surgical treatment are only considered for patients who develop resistance to diuretics or refractory ascites. Our case report concerns a patient with liver cirrhosis and severe ascites. Triple combination of diuretics was prescribed at the beginning of hospitalization. The patient showed poor response to these diuretics. Despite subsequent dose elevation of diuretics, no significant improvement was seen on patient’s daily urination. After adding a second-line medication midodrine to the patient, his daily urination was markedly increased. Significant improvements on clinical manifestations, such as lower limbs edema, waistline and body weight, were also observed. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。